Please use this identifier to cite or link to this item:
|Title:||The next step in increasing the efficacy of PRRT: Preclinical studies in vicvo and in vitro with 213Bi-[DOTA0,Tyr3]-octreotate|
|Authors:||CHAN Ho Sze; KONIJNENBERG M.w.; DE BLOIS Erik; KOELEWIJN S.j.; ANDERSON Tamara; NYSUS Monique; BREEMAN W.a.p.; ATCHER Robert; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; NORENBERG Jeffrey; DE JONG Marion|
|Citation:||EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING vol. 42 no. S1 p. S203 ; OP489|
|Type:||Articles in periodicals and books|
|Abstract:||Peptide Receptor RadioTherapy shows a reasonable objective response rate of 30-35% with the use of 177Lu-[DOTA0,Tyr3]-octreotate (177Lu-DOTATATE). Alpha-particle emitters can augment the therapeutic efficacy of PRRT and make it exceptional, especially in small tumours and metastasis cell clusters. In preclinical studies with alpha-emitter labeled peptides high specific activity is required, because of the high-affinity, but low-capacity of tumour cell receptors. The stability of -radiopeptides should be maintained until receptor mediated uptake, both in vivo as in vitro , to minimize off-targeting effects. Also the radio-peptide should have rapid uptake ,high retention in tumour tissue and high clearance capacity from normal tissue. In this study we optimized the application of 213Bi-[DOTA0,Tyr3]-octreotate (213Bi-DOTATATE) for TAT in vitro and in vivo. We investigated in various somatostatin receptor-positive tumour models in mice the therapeutic efficacy of 213Bi-DOTATATE. The labelling procedure for 213Bi-DOTATATE was chemically optimized for preclinical applications.|
|JRC Directorate:||Nuclear Safety and Security|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.